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Background: Quitting smoking is the most effective intervention to reduce
mortality in patients with coronary artery disease who smoke. Our department
has implemented an institutional program to identify and treat all smokers
admitted to the department.
Objectives: The objectives of the present paper are to describe core ele-
ments of this program and present data concerning its reach and effectiveness.
Program description: The goal of the program is to increase the number
of smokers who are abstinent from smoking six months after a coronary artery
disease-related hospitalization.
Results: Between January 2009 and April 2009, almost 109 smokers were
identified at admission, and 72.5% received intervention to help them quit
smoking. The average age was 52.6+/-8 years in the group “with intervention”
and 53.6+/-7 in the group “without intervention” The smoking status of our
patients was similar between the two groups: in fact, the average age of onset
of active smoking patients was 18.6 years in group “without intervention” and
19.4 years in group “with intervention” (p=0.41). At six-month follow-up,
76.7% of those receiving intervention were smoke-free against 55.7% of the
group “without intervention” (p=0.04). In univariate analysis the absence of
smoking intervention was predictive of MACCE in the medium term
(OR=0.2, 95% CI [0.1 to 0.8]). In multivariate logistic regression analysis,
predictors of smoking at six months after a coronary artery disease-related
hospitalization were: the absence of receiving intervention at admission, the
age of onset of smoking <20 years and the Fagerstrom score at admission> 7.
Conclusions: Hospitalization for coronary artery disease provides an impor-
tant opportunity to intervene with smokers when their motivation to quit is
high. An institutional approach reinforces the importance of smoking cessation
in this patient population and increases the rate of smoking cessation. Post hos-
pitalization quit rates should be a benchmark of cardiac program performance.
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Background: This prospective study evaluated pre-hospital anti-throm-
botic association of bivalirudin (bolus 0.5 mg/kg followed by an infusion of
1.75 mg/kg/ hour) and prasugrel (60 mg loading dose) on in-hospital outcome
in patients with acute myocardial infarction treated by primary angioplasty.
Methods and results: From June 2010 to October 2011 seventy-one
consecutive patients of 54.2±9.2 years old were included, including 27 patients
(38.0%) with anterior myocardial infarction and 15 patients (21.1%) with a
TIMI risk score >2. The culprit artery was occluded in 46 patients (64.8%).
Primary coronary angioplasty was performed 5.0±8.6 hours after symptom
onset, with radial access in 58 patients (81.7%). TIMI III culprit vessel reca-
nalisation was obtained in 71 patients (100%). Angioplasty procedure used
1.1±0.7 stents with effective thrombectomy in 31 patients (60.7%) in 51
thrombectomy attempts. AntiIIBIIIA glycoprotein treatment was administered
during angioplasty in 15 patients (21.1%). Peak troponin I reached
211.9±882.9 ng / ml, left ventricular ejection fraction was 51.6±9.4%. 
During hospitalization we observed a MACE rate of 4.2% (1 death, 1 ischemic
target vessel revascularisation and 1 reinfarction) and no stent thrombosis.
Bleeding complication rate was 2.6% according to HORIZON criteria and 0%
for severe or intermediate bleeding and 2.6% for moderate bleeding according
to GUSTO classification.
Conclusion: In-hospital outcome in patients treated by primary angioplasty
after pre-hospital bivilarudine and prasugrel treatment seems to have a low
risk of ischemic and bleeding complications.
045
Is there a protective effect of statins in contrast-induced nephropathy
after coronary angiography?
Sonia Hamdi, Wiem Selmi, Aymen Elhraiech, Mahdi Chakroun, Talel
Trimech, Walid Jomaa, Khaldoun Ben Hamda, Faouzi Maatouk
CHU Fattouma Bourguiba, Cardiologie B, Monastir, Tunisie
Background: Contrast-induced nephropathy (CIN) is a frequent complica-
tion after coronary angiography. In the exclusion of saline hydration, the
effectiveness of other means of prevention remains unclear, and almost poor.
Because of its pleotropic effects, statins have been used in CIN prevention, but
data remains controversial.
Objective: to evaluate the benefit of statins in the prevention of CIN after
coronary angiography.
Methods: We used the database of a randomized controlled trial conducted
in our department during the period March to November 2010 to study the
effectiveness of ascorbic acid in the prevention of CIN. Patients undergoing
coronary angiography were randomly assigned to a saline hydration preven-
tion protocol or a saline hydration associated to ascorbic acid protocol. The
primary endpoint was the occurrence of CIN defined as a creatinin arise of
more than 25% the baseline level during the following 48 to 72 hours. The
relationship between statin intake at baseline and CIN incidence was retro-
spectively evaluated using a Chi-square test.
Results: Among the 202 patients included, 126 (62.3%) were treated with
statins. There was no significant difference between the two groups
concerning the baseline characteristics, particularly in ascorbic acid treatment
(p=0.94). CIN incidence dropped from 20.8% in the patients not taking statins
to 11.7% in those treated with statins. This resulted in a tendency (p=0.08) but
difference wasn’t statistically significant, probably due to the small sample of
the population.
Conclusion: In our study, treatment with statins led to a trend to reduce
CIN incidence. The small sample of the population couldn’t allow stronger
conclusion. Statins seem to be promising but larger trials are needed.
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Aims: The drug-eluting stents reduce restenosis rate compared to bare
metal stents. The clinical efficacy is greater in some subgroups of patients at
high risk of restenosis. The aim of this study is to evaluate the use of drug-
eluting stent based on the recommendations of the French Society of Cardiology
and his impact on the restenosis rate at 2 years.
Methods: We included all patients who had coronary angioplasty with
stenting in 2008. We evaluated the percentage of drug-eluting stent, the pro-
portion of patients for which the French recommendations have been fol-
lowed, and the rate of clinical restenosis at 2 years.
Results: Four hundred and seventy-nine angioplasties were performed in
2008. The percentage of drug-eluting stents was 21.8%. Acute coronary syn-
drome with or without elevation of the ST segment were the main indications
of angioplasty (67.9%). For the 115 drug-eluting stents implanted in 2008,
French recommendations were followed in 93% of cases (107 stents). For
89 patients who received DES, these recommendations were followed in 91%
of cases (81 patients). The clinical restenosis rate at two years evaluated in
89% of patients was 5.6%. The rate of in-stent restenosis in bare metal and
drug-eluting stents were 5.9% and 3.7%.
